News

Startups

Americas

Ventaris Surgical Secures $30 Million Series A to Modernize Kidney Stone Treatment

Ventaris Surgical has raised $30 million to advance a digital ureteroscopic system designed for more complete kidney stone clearance.

Ventaris Surgical has raised $30 million to advance a digital ureteroscopic system designed for more complete kidney stone clearance.

Ventaris Surgical has raised $30 million to advance a digital ureteroscopic system designed for more complete kidney stone clearance.

NewDecoded

Published Jan 12, 2026

Jan 12, 2026

3 min read

Ventaris Surgical, a medical device company in San Carlos, California, has secured $30 million in Series A funding to propel its next-generation kidney stone treatment system. The round was led by Longitude Capital, with participation from Vensana Capital and existing backers. This capital infusion is designated for clinical development and navigating regulatory pathways toward a commercial launch. The company aims to redefine ureteroscopic procedures by ensuring more complete stone clearance. Traditional surgery often leaves behind residual fragments that can cause recurrence or further pain for the patient. Ventaris Surgical is developing a specialized system that streamlines urologic interventions, addressing the technical constraints and physical fatigue that often hinder surgeon performance.

The technology behind the platform focuses on eliminating procedural friction through advanced digital integration. By utilizing smart sensors and potentially AI-driven monitoring, the system provides real-time feedback during the breaking and removal of stones. These intelligent features help surgeons manage intrarenal pressure and optimize suction power, turning a manual task into a data-assisted surgical workflow.

As part of the investment, Varun Gupta and Justin Klein have joined the Ventaris Board of Directors. CEO Surag Mantri emphasized that the goal is to allow urologists to focus on clinical success rather than fighting against their tools. The presence of board member Amir Abolfathi adds further industry expertise to the leadership team as they scale operations.

With the global market for kidney stone management expanding, the move toward active aspiration technology is accelerating. Ventaris plans to use the Series A proceeds to hit commercial milestones and secure necessary FDA clearance. The funding ensures the company is well-positioned to challenge current standards in urological care by providing a more predictable and repeatable outcome for every case.


Decoded Take

Decoded Take

Decoded Take

The backing of heavyweight MedTech investors like Longitude Capital and Vensana Capital highlights a significant trend toward intelligent suction in urology. As startups like Ventaris integrate sensor-driven feedback and aspiration, they are effectively bridging the gap between manual baskets and fully automated surgical robots. This shift suggests that the future of kidney stone treatment will rely less on surgeon dexterity alone and more on systems that use software to ensure no fragments are left behind, making Ventaris a prime target for future acquisition by major industry players.

Share this article

Related Articles

Related Articles

Related Articles